Electrofisiología Cardíaca Celular

Kirchhof, P; Benussi, S; Kotecha, D; Ahlsson, A; Atar, D; Casadei, B; Castella, M; Diener, HC; Heidbuchel, H; Hendriks, J; Hindricks, G; Manolis, AS; Oldgren, J; Popescu, BA; Schotten, U; Van Putte, B; Vardas, P; Agewall, S; Camm, J; Esquivias, GB; Budts, W; Carerj, S; Casselman, F; Coca, A; De Caterina, R; Deftereos, S; Dobrev, D; Ferro, JM; Filippatos, G; Fitzsimons, D; Gorenek, B; Guenoun, M; Hohnloser, SH; Kolh, P; Lip, GYH; Manolis, A; McMurray, J; Ponikowski, P; Rosenhek, R; Ruschitzka, F; Savelieva, I; Sharma, S; Suwalski, P; Tamargo, JL; Taylor, CJ; Van Gelder, IC; Voors, AA; Windecker, S; Zamorano, JL; Zeppenfeld, K.

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

EUROPACE. 2016; 18(11): Nº de citas: 3476 [doi:10.1093/europace/euw295]

Canon, S; Caballero, R; Herraiz-Martinez, A; Perez-Hernandez, M; Lopez, B; Atienza, F; Jalife, J; Hove-Madsen, L; Delpon, E; Bernad, A.

miR-208b upregulation interferes with calcium handling in HL-1 atrial myocytes: Implications in human chronic atrial fibrillation

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY. 2016; 99: 162-173 Nº de citas: 64 [doi:10.1016/j.yjmcc.2016.08.012]

Zamorano, JL; Lancellotti, P; Munoz, DR; Aboyans, V; Asteggiano, R; Galderisi, M; Habib, G; Lenihan, DJ; Lip, GYH; Lyon, AR; Lopez Fernandez, T; Mohty, D; Piepoli, MF; Tamargo, J; Torbicki, A; Suter, TM; Zamorano, JL; Aboyans, V; Achenbach, S; Agewall, S; Badimon, L; Baron-Esquivias, G; Baumgartner, H; Bax, JJ; Bueno, H; Carerj, S; Dean, V; Erol, C; Fitzsimons, D; Gaemperli, O; Kirchhof, P; Kolh, P; Lancellotti, P; Lip, GYH; Nihoyannopoulos, P; Piepoli, MF; Ponikowski, P; Roffi, M; Torbicki, A; Carneiro, AV; Windecker, S; Achenbach, S; Minotti, G; Agewall, S; Badimon, L; Bueno, H; Cardinale, D; Carerj, S; Curigliano, G; de Azambuja, E; Dent, S; Erol, C; Ewer, MS; Farmakis, D; Fietkau, R; Fitzsimons, D; Gaemperli, O; Kirchhof, P; Kohl, P; McGale, P; Ponikowski, P; Ringwald, J; Roffi, M; Schulz-Menger, J; Stebbing, J; Steiner, RK; Szmit, S; Carneiro, AV; Windecker, S.

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

EUROPEAN HEART JOURNAL. 2016; 37(36): 2768-2801 Nº de citas: 1429 [doi:10.1093/eurheartj/ehw211]

Romero, M; Jimenez, R; Toral, M; Leon-Gomez, E; Gomez-Guzman, M; Sanchez, M; Zarzuelo, MJ; Rodriguez-Gomez, I; Rath, G; Tamargo, J; Perez-Vizcaino, F; Dessy, C; Duarte, J.

Vascular and Central Activation of Peroxisome Proliferator-Activated Receptor-beta Attenuates Angiotensin II-Induced Hypertension: Role of RGS-5

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2016; 358(1): 151-163 Nº de citas: 16 [doi:10.1124/jpet.116.233106]

Zannad, F; Stough, WG; Lipicky, RJ; Tamargo, J; Bakris, GL; Borer, JS; Garcia, MDA; Hadjadj, S; Koenig, W; Kupfer, S; McCullough, PA; Mosenzon, O; Pocock, S; Scheen, AJ; Sourij, H; Van der Schueren, B; Stahre, C; White, WB; Calvo, G.

Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion

European Heart Journal-Cardiovascular Pharmacotherapy. 2016; 2(3): 200-205 Nº de citas: 34 [doi:10.1093/ehjcvp/pvw007]

Toral, M; Romero, M; Jimenez, R; Robles-Vera, I; Tamargo, J; Martinez, MC; Perez-Vizcaino, F; Duarte, J.

Role of UCP2 in the protective effects of PPAR beta/delta activation on lipopolysaccharide-induced endothelial dysfunction

BIOCHEMICAL PHARMACOLOGY. 2016; 110: 25-36 Nº de citas: 27 [doi:10.1016/j.bcp.2016.05.004]

Matamoros, M; Perez-Hernandez, M; Guerrero-Serna, G; Amoros, I; Barana, A; Nunez, M; Ponce-Balbuena, D; Sacristan, S; Gomez, R; Tamargo, J; Caballero, R; Jalife, J; Delpon, E.

Nav1.5 N-terminal domain binding to alpha 1-syntrophin increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels

CARDIOVASCULAR RESEARCH. 2016; 110(2): 279-290 Nº de citas: 67 [doi:10.1093/cvr/cvw009]

Schmidt, M; Lamberts, M; Olsen, AMS; Fosboll, E; Niessner, A; Tamargo, J; Rosano, G; Agewall, S; Kaski, JC; Kjeldsen, K; Lewis, BS; Torp-Pedersen, C.

Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology

EUROPEAN HEART JOURNAL. 2016; 37(13): 1015-26 Nº de citas: 106 [doi:10.1093/eurheartj/ehv505]

Delpon, MT; Demelo-Rodriguez, P; Ballesteros, JCC; de la Cruz, LV.

Psoas abscess caused by Staphylococcus lugdunensis

REVISTA ARGENTINA DE MICROBIOLOGIA. 2016; 48(2): 119-121 Nº de citas: 3 [doi:10.1016/j.ram.2016.02.005]

Perez-Hernandez, M; Matamoros, M; Barana, A; Amoros, I; Gomez, R; Nunez, M; Sacristan, S; Pinto, A; Fernandez-Aviles, F; Tamargo, J; Delpon, E; Caballero, R.

Pitx2c increases in atrial myocytes from chronic atrial fibrillation patients enhancing I-Ks and decreasing I-Ca,I-L

CARDIOVASCULAR RESEARCH. 2016; 109(3): 431-441 Nº de citas: 56 [doi:10.1093/cvr/cvv280]

Ambrosio, G; Tamargo, J; Grant, PJ.

Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence

Diabetes & Vascular Disease Research. 2016; 13(2): 98-112 Nº de citas: 10 [doi:10.1177/1479164115609028]

Ferrari, R; Bertini, M; Blomstrom-Lundqvist, C; Dobrev, D; Kirchhof, P; Pappone, C; Ravens, U; Tamargo, J; Tavazzi, L; Vicedomini, GG.

An update on atrial fibrillation in 2014: From pathophysiology to treatment

INTERNATIONAL JOURNAL OF CARDIOLOGY. 2016; 203: 22-29 Nº de citas: 58 [doi:10.1016/j.ijcard.2015.10.089]

Camm, AJ; Manolis, A; Ambrosio, G; Daly, C; Komajda, M; de Sa, EL; Lopez-Sendon, JL; Mugelli, A; Muggli, F; Tamargo, J.

Unresolved issues in the management of chronic stable angina

INTERNATIONAL JOURNAL OF CARDIOLOGY. 2015; 201: 200-207 Nº de citas: 26 [doi:10.1016/j.ijcard.2015.08.045]

Tamargo, J; Castellano, JM; Fuster, V.

The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention

INTERNATIONAL JOURNAL OF CARDIOLOGY. 2015; 201: 15 Nº de citas: 36 [doi:10.1016/S0167-5273(15)31028-7]

Rosano GM; Lewis B; Agewall S; Wassmann S; Vitale C; Schmidt H; Drexel H; Patak A; Torp-Pedersen C; Kjeldsen KP; Tamargo J.

Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC.

EUROPEAN HEART JOURNAL. 2015; 36(40): 2677-2680 Nº de citas: 149 [doi:10.1093/eurheartj/ehv161]

Tamargo, J; Le Heuzey, JY; Mabo, P.

Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2015; 71(5): 549-567 Nº de citas: 191 [doi:10.1007/s00228-015-1832-0]

Tamargo, J; Caballero, R; Delpon, E.

Cancer Chemotherapy and Cardiac Arrhythmias: A Review

DRUG SAFETY. 2015; 38(2): 129-152 Nº de citas: 120 [doi:10.1007/s40264-014-0258-4]

Tamargo, J; Duarte, J; Ruilope, LM.

New Antihypertensive Drugs Under Development

CURRENT MEDICINAL CHEMISTRY. 2015; 22(3): 305-342 Nº de citas: 19